Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease

Behavioural Brain Research

Volumn 208, Issue 1, 2010, Pages 137-143

  Branchi, Igor ^a   D'Andrea, Ivana ^a   Armida, Monica ^a   Carnevale, Daniela ^a   Ajmone Cat, Maria Antonietta ^a   Pèzzola, Antonella ^a   Potenza, Rosa Luisa ^a   Morgese, Maria Grazia ^b   Cassano, Tommaso ^b   Minghetti, Luisa ^a   Popoli, Patrizia ^a   Alleva, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Anxiety; BDNF; Emotional; F2 isoprostane; Oxidative stress; Prostaglandin E2

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOOXYGENASE 2; DOPAMINE; HOMOVANILLIC ACID; ISOPROSTANE DERIVATIVE; OXIDOPAMINE; PROSTAGLANDIN E2; SEROTONIN; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ADRENERGIC RECEPTOR STIMULATING AGENT; BIOGENIC AMINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINE BRAIN LEVEL; EMOTIONALITY; HIPPOCAMPUS; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; ANIMAL; BRAIN LEVEL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; EXPLORATORY BEHAVIOR; LOCOMOTION; MAZE TEST; METABOLISM; PATHOLOGY; SWIMMING;

ADRENERGIC AGENTS; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DINOPROST; DINOPROSTONE; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; OXIDOPAMINE; PARKINSON DISEASE; SWIMMING;

EID: 77951931079     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.11.020     Document Type: Article

References (68)

1. Allain H., Schuck S., Mauduit N. Depression in Parkinson's disease. BMJ 2000, 320:1287-1288.
2. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 2008, 210:182-193.
3. Amalric M., Moukhles H., Nieoullon A., Daszuta A. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 1995, 7:972-980.
4. Anastasia A., Torre L., de Erausquin G.A., Masco D.H. Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease. J Neurochem 2009, 109:755-765.
5. Asanuma M., Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des 2008, 14:1428-1434.
6. Bankiewicz K.S., Sanchez-Pernaute, R., Oiwa, Y., Kohutnicka M., Cummins A., Eberling J. Preclinical models of Parkinson's disease. In: G.R. Gerfen, et al. (eds.) Curr Protoc Neurosci. Hoboken: John Wiley and Sons, Inc.; 1999; vol. 2.
7. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005, 25:6251-6259.
8. Belzung C. Measuring rodent exploratory behavior. Handbook of molecular-genetic techniques for brain and behavior research 1999, vol. 13:738-747. Elsevier, Amsterdam.
9. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000, 62:63-88.
10. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
11. Branchi I., Alleva E. Communal nesting, an early social enrichment, increases the adult anxiety-like response and shapes the role of social context in modulating the emotional behavior. Behav Brain Res 2006, 172:299-306.
12. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., et al. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008, 86:2050-2061.
13. Branchi I., D'Andrea I., Fiore M., Di Fausto V., Aloe L., Alleva E. Early social enrichment shapes social behavior and nerve growth factor and brain-derived neurotrophic factor levels in the adult mouse brain. Biol Psychiatry 2006, 60:690-696.
14. Branchi I., D'Andrea I., Sietzema J., Fiore M., Di Fausto V., Aloe L., et al. Early social enrichment augments adult hippocampal BDNF levels and survival of BrdU-positive cells while increasing anxiety- and " depression" -like behavior. J Neurosci Res 2006, 83:965-973.
15. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002, 17:445-454.
16. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006, 96:1718-1727.
17. Cassano T., Gaetani S., Morgese M.G., Macheda T., Laconca L., Dipasquale P., et al. Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res 2009, 34:1417-1426.
18. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
19. Chenu F., Dailly E., Bourin M. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol 2007, 17:187-193.
20. De Leonibus E., Pascucci T., Lopez S., Oliverio A., Amalric M., Mele A. Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl) 2007, 194:517-525.
21. de Meira Santos Lima M., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S., Vital M.A. Different Parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101:117-125.
22. Di Matteo V., Pierucci M., Esposito E., Crescimanno G., Benigno A., Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res 2008, 172:423-463.
23. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205:295-312.
24. Fox M.J. Lucky man: a memoir 2002, Hyperion, New York.
25. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7:927-938.
26. Frick K.M., Stillner E.T., Berger-Sweeney J. Mice are not little rats: species differences in a one-day water maze task. Neuroreport 2000, 11:3461-3465.
27. George S., van den Buuse M., San Mok S., Masters C.L., Li Q.X., Culvenor J.G. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 2008, 210:788-792.
28. Greco A., Minghetti L. Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Curr Neurovasc Res 2004, 1:341-354.
29. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
30. Huot P., Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 2007, 101:1441-1447.
31. Karstaedt P.J., Kerasidis H., Pincus J.H., Meloni R., Graham J., Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 1994, 126:25-30.
32. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
33. Lang A.E., Quinn N., Brincat S., Marsden C.D., Parkes J.D. Pergolide in late-stage Parkinson disease. Ann Neurol 1982, 12:243-247.
34. Langston J.W. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 2006, 59:591-596.
35. Lauterbach E.C., Duvoisin R.C. Anxiety disorders in familial Parkinsonism. Am J Psychiatry 1991, 148:274.
36. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16:110-123.
37. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005, 194:66-75.
38. Macht M., Schwarz R., Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta Neurol Scand 2005, 111:95-101.
39. Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., MacPhee G., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22:1623-1629.
40. Menza M.A., Robertson-Hoffman D.E., Bonapace A.S. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993, 34:465-470.
41. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem 2007, 42:127-141.
42. Minghetti L., Greco A., Cardone F., Puopolo M., Ladogana A., Almonti S., et al. Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000, 59:866-871.
43. Morgese M.G., Cassano T., Cuomo V., Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 2007, 208:110-119.
44. Morgese M.G., Cassano T., Gaetani S., Macheda T., Laconca L., Dipasquale P., et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int 2009, 54:56-64.
45. Numan S., Seroogy K.B. Increased expression of trkB mRNA in rat caudate-putamen following 6-OHDA lesions of the nigrostriatal pathway. Eur J Neurosci 1997, 9:489-495.
46. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
47. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 330:156-160.
48. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2000, Academic Press, New York.
49. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
50. Richter F., Hamann M., Richter A. Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice. Brain Res 2008, 1188:148-156.
51. Roeltgen D.P., Schneider J.S. Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder. J Child Neurol 1991, 6(Suppl.):S82-89.
52. Schmidt R.H., Björklund A., Stenevi U., Dunnett S.B., Gage F.H. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl 1983, 522:19-28.
53. Scholtissen B., Deumens R., Leentjens A.F., Schmitz C., Blokland A., Steinbusch H.W., et al. Functional investigations into the role of dopamine and serotonin in partial bilateral striatal 6-hydroxydopamine lesioned rats. Pharmacol Biochem Behav 2006, 83:175-185.
54. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 69:308-312.
55. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996, 49:215-266.
56. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000, 30:171-182.
57. Sharma V., Smith A. A case of mania following the use of pramipexole. Am J Psychiatry 2007, 164:351.
58. Singh A., Althoff R., Martineau R.J., Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease. Am J Psychiatry 2005, 162:814-815.
59. Sivam S.P. Dopaminergic modulation of serotonin metabolism in rat striatum: a study with dopamine uptake inhibitor GBR-12909. Life Sci 1995, 56:PL467-472.
60. Szczypka M.S., Rainey M.A., Kim D.S., Alaynick W.A., Marck B.T., Matsumoto A.M., et al. Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci USA 1999, 96:12138-12143.
61. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003, 100:5473-5478.
62. Towle A.C., Criswell H.E., Maynard E.H., Lauder J.M., Joh T.H., Mueller R.A., et al. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: an anatomical, biochemical and pharmacological study. Pharmacol Biochem Behav 1989, 34:367-374.
63. Tyurina Y.Y., Kapralov A.A., Jiang J., Borisenko G.G., Potapovich A.I., Sorokin A., et al. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res 2006, 1093:71-82.
64. Vazquez A., Jimenez-Jimenez F.J., Garcia-Ruiz P., Garcia-Urra D. " Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand 1993, 87:14-18.
65. Walitza S., Melfsen S., Herhaus G., Scheuerpflug P., Warnke A., Muller T., et al. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm Suppl 2007, 72:311-315.
66. Walsh K., Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001, 77:89-93.
67. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11:371-386.
68. Zhou J., Pliego-Rivero B., Bradford H.F., Stern G.M. The BDNF content of postnatal and adult rat brain: the effects of 6-hydroxydopamine lesions in adult brain. Brain Res Dev Brain Res 1996, 97:297-303.